首页 > 最新文献

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences最新文献

英文 中文
Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report. 糖皮质激素和白蛋白成功治疗酒精性肝硬化继发的急性慢性肝衰竭1例
Pub Date : 2022-06-01 DOI: 10.1007/s40199-021-00420-w
Jiuqin Zhou, Si Chen, Lin Zhang, Yongzhen Zhai

Glucocorticoids are used as a first-line treatment for severe alcoholic hepatitis, and albumin reduces both the number of hospitalizations and mortality in patients with decompensated cirrhosis. However, for acute-on-chronic liver failure (ACLF), there is no definitive evidence that glucocorticoid therapy is beneficial. In this case report, we describe a male patient who developed into ACLF based on alcoholic cirrhosis, whose symptoms and clinical indicators continued to deteriorate after initial symptomatic treatment. The patient's condition gradually improved after low-dose glucocorticoid therapy, and long-term albumin supplementation resulted in a satisfactory outcome.

糖皮质激素被用作严重酒精性肝炎的一线治疗,白蛋白可降低失代偿期肝硬化患者的住院人数和死亡率。然而,对于急性慢性肝衰竭(ACLF),没有明确的证据表明糖皮质激素治疗是有益的。在本病例报告中,我们描述了一名男性患者在酒精性肝硬化的基础上发展为ACLF,其症状和临床指标在最初的对症治疗后继续恶化。患者经低剂量糖皮质激素治疗后病情逐渐好转,长期补充白蛋白治疗效果满意。
{"title":"Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report.","authors":"Jiuqin Zhou,&nbsp;Si Chen,&nbsp;Lin Zhang,&nbsp;Yongzhen Zhai","doi":"10.1007/s40199-021-00420-w","DOIUrl":"https://doi.org/10.1007/s40199-021-00420-w","url":null,"abstract":"<p><p>Glucocorticoids are used as a first-line treatment for severe alcoholic hepatitis, and albumin reduces both the number of hospitalizations and mortality in patients with decompensated cirrhosis. However, for acute-on-chronic liver failure (ACLF), there is no definitive evidence that glucocorticoid therapy is beneficial. In this case report, we describe a male patient who developed into ACLF based on alcoholic cirrhosis, whose symptoms and clinical indicators continued to deteriorate after initial symptomatic treatment. The patient's condition gradually improved after low-dose glucocorticoid therapy, and long-term albumin supplementation resulted in a satisfactory outcome.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"30 1","pages":"153-157"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114176/pdf/40199_2021_Article_420.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10249542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management and control of intraocular pressure applying macitentan hydrogel film formulation: improved effect of surfactant and cosurfactant system. 应用马西坦水凝胶膜配方管理和控制眼压:表面活性剂和助表面活性剂体系的改善效果。
Pub Date : 2022-06-01 DOI: 10.1007/s40199-021-00428-2
Sidhartha Sankar Hota, Souvik Nandi, Subrata Mallick

Background: Macitentan blocks endothelin receptors in order to control the pulmonary arterial hypertension (PAH). Oral administration of macitentan is associated with painful urination and troubled breathing.

Objectives: Formulated macitentan hydrogel film was used for examining the control of intraocular pressure, and the effect of surfactant and cosurfactant was studied.

Methods: Macitentan ocular film formulation has been prepared in hydroxypropyl methylcellulose (HPMC) matrix system using different surfactant/co-surfactant system, and intraocular pressure was monitored on normotensive rabbit eyes after application in the cul-de-sac.

Results: The solid state characterization of the film indicated amorphisation of macitentan and no issues regarding major incompatibility was observed. Combination of surfactant, co-surfactant and hydrophilic co-solvent systems in the said films markedly improved the drug release and mucosal tissue permeation. Presence of PEG and Transcutol significantly improved ex vivo corneal permeation of MP and MT respectively compared to other films. Transcutol (MT) exhibited greatest difference among the formulations by improving the vesicular bilayer fluidity and reducing the mucosal tissue barrier facilitating the transcorneal diffusion. A combination of diffusion and erosion control behavior was observed in drug release and corneal permeation of the films due to the balanced liquid penetration and polymeric chain relaxation rate. MP and MT films were used for further in vivo studies to achieve possible effective and prolonged control of intraocular pressure. In vivo study has revealed the reduction in intraocular pressure upto about 23 % when tested on normotensive rabbit model. The films has managed to lower the IOP upto 3 h.

Conclusion: Developed macitentan hydrogel film containing Transcutol (MT) could have a high potential for the control and management of ocular hypertension after topical application.

背景:马西坦阻断内皮素受体以控制肺动脉高压(PAH)。口服马西坦可引起排尿疼痛和呼吸困难。目的:采用配制的马西坦水凝胶膜检查眼压的控制情况,并研究表面活性剂和助表面活性剂的作用。方法:在羟丙基甲基纤维素(HPMC)基质体系中,采用不同的表面活性剂/助表面活性剂体系制备马西坦眼膜制剂,并在正常血压家兔眼内应用后监测眼压。结果:薄膜的固态表征表明马西坦的非晶化,没有观察到主要不相容的问题。表面活性剂、助表面活性剂和亲水共溶剂体系在上述膜中的组合显著改善了药物释放和粘膜组织渗透。与其他膜相比,PEG和Transcutol的存在分别显著提高了MP和MT的离体角膜渗透。通过改善囊泡双分子层流动性和降低粘膜组织屏障促进经角膜扩散,各剂型间差异最大。由于液体渗透和聚合物链弛豫速率的平衡,在药物释放和角膜渗透中观察到扩散和侵蚀结合的控制行为。MP和MT膜用于进一步的体内研究,以实现可能有效和持久的眼压控制。体内研究表明,在正常血压的家兔模型上测试时,眼压降低约23%。结论:经外用含Transcutol (MT)的马西坦水凝胶膜在控制和治疗高眼压方面具有很大的潜力。
{"title":"Management and control of intraocular pressure applying macitentan hydrogel film formulation: improved effect of surfactant and cosurfactant system.","authors":"Sidhartha Sankar Hota,&nbsp;Souvik Nandi,&nbsp;Subrata Mallick","doi":"10.1007/s40199-021-00428-2","DOIUrl":"https://doi.org/10.1007/s40199-021-00428-2","url":null,"abstract":"<p><strong>Background: </strong>Macitentan blocks endothelin receptors in order to control the pulmonary arterial hypertension (PAH). Oral administration of macitentan is associated with painful urination and troubled breathing.</p><p><strong>Objectives: </strong>Formulated macitentan hydrogel film was used for examining the control of intraocular pressure, and the effect of surfactant and cosurfactant was studied.</p><p><strong>Methods: </strong>Macitentan ocular film formulation has been prepared in hydroxypropyl methylcellulose (HPMC) matrix system using different surfactant/co-surfactant system, and intraocular pressure was monitored on normotensive rabbit eyes after application in the cul-de-sac.</p><p><strong>Results: </strong>The solid state characterization of the film indicated amorphisation of macitentan and no issues regarding major incompatibility was observed. Combination of surfactant, co-surfactant and hydrophilic co-solvent systems in the said films markedly improved the drug release and mucosal tissue permeation. Presence of PEG and Transcutol significantly improved ex vivo corneal permeation of MP and MT respectively compared to other films. Transcutol (MT) exhibited greatest difference among the formulations by improving the vesicular bilayer fluidity and reducing the mucosal tissue barrier facilitating the transcorneal diffusion. A combination of diffusion and erosion control behavior was observed in drug release and corneal permeation of the films due to the balanced liquid penetration and polymeric chain relaxation rate. MP and MT films were used for further in vivo studies to achieve possible effective and prolonged control of intraocular pressure. In vivo study has revealed the reduction in intraocular pressure upto about 23 % when tested on normotensive rabbit model. The films has managed to lower the IOP upto 3 h.</p><p><strong>Conclusion: </strong>Developed macitentan hydrogel film containing Transcutol (MT) could have a high potential for the control and management of ocular hypertension after topical application.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"30 1","pages":"39-47"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114230/pdf/40199_2021_Article_428.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10844205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcineurin inhibitors and related medicines: a cohort study examining England's primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021). 降钙素抑制剂及相关药物:一项队列研究,考察 COVID-19 大流行期间(2019 年 1 月至 2021 年 3 月)英格兰初级保健处方的变化。
Pub Date : 2022-06-01 Epub Date: 2022-01-24 DOI: 10.1007/s40199-021-00431-7
Ravina Barrett

Purpose: To examine the impact of the COVID-19 pandemic on calcineurin inhibitors and related prescriptions for community patients in England.

Methods: Data from all primary-care patients who had calcineurin inhibitors prescriptions, dispensed in the community in England were included. Descriptive statistics and interrupted time series analysis over 27 months (15 months before and 12 months after 1st lockdown) was evaluated.

Results: Descriptive statistics show that mean values have declined since the pandemic's onset. Over the 27 months: mean Tacrolimus 865,045 doses, standard deviation (SD) 76,147 doses, with 95% CI 834,923, 895,168, (min 567,508, max 1,010,900), ciclosporin 315,496 doses, SD 40,094, 95% CI 299,635, 331,356 (min 191,281, max 382,253) and sirolimus 21,384 doses, SD 2,610, 95% CI 20,352, 22,417 (min 13,022, max 26,156). Analysis of variance between the pre- and post- periods show significant variations in quantities of tacrolimus F 7.432, p = 0.012, ciclosporin F 33.147, p < 0.001 and sirolimus F 18.596, p < 0.001 (1df), mirrored in price analysis. The Interrupted Time Series (ARIMA Modelling) shows declining trends. After the pandemic's onset, a statistically significant downward trend in quantity for tacrolimus p = 0.008 is observed, with an estimated monthly decline of 14,524 doses, ciclosporin p = 0.185, with an estimated decline of 2,161 doses and sirolimus p = 0.002 with an estimated decline of 485 doses, along with declining prices.

Conclusion: A decrease in prescription medicines use raises concerns for the care of (renal) transplant patients. Patients are encouraged to discuss their planned care with their doctor, secure supplies and remain adherent to their medication.

目的:研究 COVID-19 大流行对英格兰社区患者的降钙素抑制剂及相关处方的影响:方法:纳入英格兰社区所有开具降钙素抑制剂处方的初级保健患者的数据。对 27 个月(第一次封锁前 15 个月和封锁后 12 个月)的描述性统计和间断时间序列分析进行了评估:描述性统计显示,自大流行开始以来,平均值有所下降。在这 27 个月中平均他克莫司 865,045 剂,标准差 (SD) 76,147 剂,95% CI 834,923, 895,168, (min 567,508, max 1,010,900), 环孢素 315,496 剂、西罗莫司 21,384 剂,标度 2,610,95% CI 20,352 至 22,417 (最少 13,022 剂,最多 26,156 剂)。前后阶段的方差分析显示,他克莫司 F 7.432,P = 0.012,环孢素 F 33.147,P 结论:处方药使用量的减少引起了人们的关注:处方药用量的减少引起了对(肾)移植患者护理的关注。我们鼓励患者与医生讨论他们的护理计划,确保药物供应并坚持用药。
{"title":"Calcineurin inhibitors and related medicines: a cohort study examining England's primary care prescription changes during the COVID-19 pandemic (January 2019 to March 2021).","authors":"Ravina Barrett","doi":"10.1007/s40199-021-00431-7","DOIUrl":"10.1007/s40199-021-00431-7","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the impact of the COVID-19 pandemic on calcineurin inhibitors and related prescriptions for community patients in England.</p><p><strong>Methods: </strong>Data from all primary-care patients who had calcineurin inhibitors prescriptions, dispensed in the community in England were included. Descriptive statistics and interrupted time series analysis over 27 months (15 months before and 12 months after 1<sup>st</sup> lockdown) was evaluated.</p><p><strong>Results: </strong>Descriptive statistics show that mean values have declined since the pandemic's onset. Over the 27 months: mean Tacrolimus 865,045 doses, standard deviation (SD) 76,147 doses, with 95% CI 834,923, 895,168, (min 567,508, max 1,010,900), ciclosporin 315,496 doses, SD 40,094, 95% CI 299,635, 331,356 (min 191,281, max 382,253) and sirolimus 21,384 doses, SD 2,610, 95% CI 20,352, 22,417 (min 13,022, max 26,156). Analysis of variance between the pre- and post- periods show significant variations in quantities of tacrolimus F 7.432, p = 0.012, ciclosporin F 33.147, p < 0.001 and sirolimus F 18.596, p < 0.001 (1df), mirrored in price analysis. The Interrupted Time Series (ARIMA Modelling) shows declining trends. After the pandemic's onset, a statistically significant downward trend in quantity for tacrolimus p = 0.008 is observed, with an estimated monthly decline of 14,524 doses, ciclosporin p = 0.185, with an estimated decline of 2,161 doses and sirolimus p = 0.002 with an estimated decline of 485 doses, along with declining prices.</p><p><strong>Conclusion: </strong>A decrease in prescription medicines use raises concerns for the care of (renal) transplant patients. Patients are encouraged to discuss their planned care with their doctor, secure supplies and remain adherent to their medication.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":" ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39963267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phytochemical analysis of Daphne pontica L. stems with their pro-apoptotic properties against DU-145 and LNCaP prostate cancer cells. 牡丹茎对DU-145和LNCaP前列腺癌细胞促凋亡特性的植物化学分析。
Pub Date : 2022-06-01 DOI: 10.1007/s40199-022-00434-y
Maryam Nikahd, Mahmoud Aghaei, Zulfiqar Ali, Seyed Ebrahim Sajjadi, Ikhlas A Khan, Mustafa Ghanadian

Background: Daphne pontica is an endemic plant grown wild in the North part of Iran, with anticancer activities.

Objectives: This study aims to analyze the phytochemistry and screen the cytotoxic activity of new bioactive compounds against a panel of cancer cells, in addition to proapototic properties against prostate cancer cells.

Method: Purification procedure was done using repeated column chromatographies by MPLC and HPLC systems. The structures were elucidated by the NMR and exact mass spectroscopy, stereochemistry by NOESY, and absolute configuration by electronic circular dichroism (ECD) spectra. Cytotoxicity was done against DU 145, LNCaP, HeLa, MCF-7, and MDA-MB 231 cells by standard MTT assay. An annexin V/PI assay was performed to measure the type of death following treatment with these compounds for 48 h, followed by the caspase-3 activity test.

Results: In this study, one new dilignan named lignopontin A (9), in addition to 13 known compounds including two phenolic acids (3, 5), one flavanone (6), one bis flavonoid (1), one cumarin glycoside (2), one mono (4) and two dicumarins (10, 11), two lignans (7, 8), and three daphnane diterpenoids (12-14) were isolated for the first time from D. pontica stems. Complete spectral data of compound 12, named as 6,7α-epoxy-5β-hydroxy-9,13,14-ortho-(4,2E)-pentadeca-2,4-diene-1-yl)-resiniferonol, and compound 14, named as 6,7α-epoxy-5β-hydroxy-9,3,14-ortho-(2,4E)-pentadeca-2,4-di-1-yl)-resiniferonol-12β-yl-acetate are reported for the first time. In the MTT assay of newly described compounds against a panel of cancer cells, compounds 9, 12, and 14 possessed moderate to potent cytotoxicity against prostate, breast, and cervical cancer cells in a dose-dependent manner. Flow cytometry analysis against prostate cancer cells indicated that the cytotoxicity of compounds 12 and 14 was due to their ability to induce apoptosis. In the case of compound 9, in Du 145 cells, cell death was mainly through apoptosis. In contrast, LNCaP cells showed both apoptosis and necrotic cell death, predominated by necrosis at the higher concentrations. Caspase-3 activity confirmed apoptosis observed in these compounds through the caspase pathway in prostate cancer cells.

Conclusion: D. pontica is a new source of dimeric phenolic compounds, including bisflavonoids, phenylpropanoid-cumarin adduct, and dilignans, as well as daphnane diterpenoids with resiniferonol core with long-chain orthoester moieties. In cytotoxicity screening, compounds 9, 12, and 14 inhibited the growth of DU-145 and LNCaP cells in a dose-dependent manner with IC50 varied from 0.9 - 27.3 and 25.2 - 87.4 μM, respectively. Among them, 9 exhibited selective growth inhibition against DU 145 treated cells. LNCaP cells demonstrated the highest sensitivity to treatment with compound 12.

背景:牡丹是伊朗北部特有的野生植物,具有抗癌作用。目的:本研究旨在分析植物化学和筛选新的生物活性化合物对一组癌细胞的细胞毒活性,以及对前列腺癌细胞的促凋亡特性。方法:采用高效液相色谱和高效液相色谱系统进行重复柱层析纯化。通过核磁共振和精确质谱、noesi立体化学和电子圆二色(ECD)绝对构型对其结构进行了表征。采用标准MTT法对DU 145、LNCaP、HeLa、MCF-7和MDA-MB 231细胞进行细胞毒性试验。用膜联蛋白V/PI测定这些化合物治疗48小时后的死亡类型,然后进行caspase-3活性测试。结果:本研究首次从蓬脱草茎中分离到1个新的木脂素A(9),以及2个酚酸(3,5)、1个黄酮(6)、1个双黄酮(1)、1个孜然苷(2)、1个单酚(4)和2个双孜然素(10,11)、2个木脂素(7,8)和3个daphnane二萜(12-14)等13个已知化合物。首次报道了化合物12 (6,7α-环氧-5β-羟基-9,13,14-邻位-(4,2e)-pentadeca-2,4-diene-1-yl)-resiniferonol)和化合物14 (6,7α-环氧-5 - β-羟基-9,3,14-邻位-(2,4e)-pentadeca-2,4-di-1-yl)-resiniferonol-12β-yl-acetate)的完整光谱数据。在新描述的化合物对一组癌细胞的MTT试验中,化合物9、12和14对前列腺、乳腺癌和宫颈癌细胞具有剂量依赖性的中等至强效细胞毒性。对前列腺癌细胞的流式细胞术分析表明,化合物12和14的细胞毒性是由于其诱导细胞凋亡的能力。在化合物9的情况下,在Du 145细胞中,细胞主要通过凋亡死亡。LNCaP细胞表现为凋亡和坏死细胞死亡,高浓度时以坏死为主。caspase -3活性证实了这些化合物通过caspase途径在前列腺癌细胞中观察到的凋亡。结论:本品是一种新的二聚酚类化合物来源,包括双黄酮类化合物、苯基丙素-香豆素加合物、茴香素,以及以长链正构酯为核心的苯胺二萜。在细胞毒性筛选中,化合物9、12和14抑制DU-145和LNCaP细胞生长呈剂量依赖性,IC50分别为0.9 ~ 27.3 μM和25.2 ~ 87.4 μM。其中9个对du145处理的细胞表现出选择性生长抑制。LNCaP细胞对化合物12的敏感性最高。
{"title":"Phytochemical analysis of Daphne pontica L. stems with their pro-apoptotic properties against DU-145 and LNCaP prostate cancer cells.","authors":"Maryam Nikahd,&nbsp;Mahmoud Aghaei,&nbsp;Zulfiqar Ali,&nbsp;Seyed Ebrahim Sajjadi,&nbsp;Ikhlas A Khan,&nbsp;Mustafa Ghanadian","doi":"10.1007/s40199-022-00434-y","DOIUrl":"https://doi.org/10.1007/s40199-022-00434-y","url":null,"abstract":"<p><strong>Background: </strong>Daphne pontica is an endemic plant grown wild in the North part of Iran, with anticancer activities.</p><p><strong>Objectives: </strong>This study aims to analyze the phytochemistry and screen the cytotoxic activity of new bioactive compounds against a panel of cancer cells, in addition to proapototic properties against prostate cancer cells.</p><p><strong>Method: </strong>Purification procedure was done using repeated column chromatographies by MPLC and HPLC systems. The structures were elucidated by the NMR and exact mass spectroscopy, stereochemistry by NOESY, and absolute configuration by electronic circular dichroism (ECD) spectra. Cytotoxicity was done against DU 145, LNCaP, HeLa, MCF-7, and MDA-MB 231 cells by standard MTT assay. An annexin V/PI assay was performed to measure the type of death following treatment with these compounds for 48 h, followed by the caspase-3 activity test.</p><p><strong>Results: </strong>In this study, one new dilignan named lignopontin A (9), in addition to 13 known compounds including two phenolic acids (3, 5), one flavanone (6), one bis flavonoid (1), one cumarin glycoside (2), one mono (4) and two dicumarins (10, 11), two lignans (7, 8), and three daphnane diterpenoids (12-14) were isolated for the first time from D. pontica stems. Complete spectral data of compound 12, named as 6,7α-epoxy-5β-hydroxy-9,13,14-ortho-(4,2E)-pentadeca-2,4-diene-1-yl)-resiniferonol, and compound 14, named as 6,7α-epoxy-5β-hydroxy-9,3,14-ortho-(2,4E)-pentadeca-2,4-di-1-yl)-resiniferonol-12β-yl-acetate are reported for the first time. In the MTT assay of newly described compounds against a panel of cancer cells, compounds 9, 12, and 14 possessed moderate to potent cytotoxicity against prostate, breast, and cervical cancer cells in a dose-dependent manner. Flow cytometry analysis against prostate cancer cells indicated that the cytotoxicity of compounds 12 and 14 was due to their ability to induce apoptosis. In the case of compound 9, in Du 145 cells, cell death was mainly through apoptosis. In contrast, LNCaP cells showed both apoptosis and necrotic cell death, predominated by necrosis at the higher concentrations. Caspase-3 activity confirmed apoptosis observed in these compounds through the caspase pathway in prostate cancer cells.</p><p><strong>Conclusion: </strong>D. pontica is a new source of dimeric phenolic compounds, including bisflavonoids, phenylpropanoid-cumarin adduct, and dilignans, as well as daphnane diterpenoids with resiniferonol core with long-chain orthoester moieties. In cytotoxicity screening, compounds 9, 12, and 14 inhibited the growth of DU-145 and LNCaP cells in a dose-dependent manner with IC<sub>50</sub> varied from 0.9 - 27.3 and 25.2 - 87.4 μM, respectively. Among them, 9 exhibited selective growth inhibition against DU 145 treated cells. LNCaP cells demonstrated the highest sensitivity to treatment with compound 12.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"30 1","pages":"85-101"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114221/pdf/40199_2022_Article_434.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10755825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review. 评估模型和模拟的预测能力,以确定吸入药物的生物等效性:一个系统的回顾。
Pub Date : 2022-06-01 DOI: 10.1007/s40199-021-00423-7
Juliet Rebello, Bill Brashier, Sharvari Shukla

Objectives: There are a multitude of different modelling techniques that have been used for inhaled drugs. The main objective of this review was to conduct an exhaustive survey of published mathematical models in the area of asthma and chronic obstructive pulmonary disease (COPD) for inhalation drugs. Additionally, this review will attempt to assess the applicability of these models to assess bioequivalence (BE) of orally inhaled products (OIPs).

Evidence acquisition: PubMed, Science Direct, Web of Science, and Scopus databases were searched from 1996 to 2020, to find studies that described mathematical models used for inhaled drugs in asthma/COPD.

Results: 50 articles were finally included in this systematic review. This research identified 22 articles on in silico aerosol deposition models, 20 articles related to population pharmacokinetics and 8 articles on physiologically based pharmacokinetic modelling (PBPK) modelling for inhaled drugs in asthma/COPD. Among all the aerosol deposition models, computational fluid dynamics (CFD) simulations are more likely to predict regional aerosol deposition pattern in human respiratory tracts. Across the population PK articles, body weight, gender, age and smoking status were the most common covariates that were found to be significant. Further, limited published PBPK models reported approximately 29 parameters relevant for absorption and distribution of inhaled drugs. The strengths and weaknesses of each modelling technique has also been reviewed.

Conclusion: Overall, while there are different modelling techniques that have been used for inhaled drugs in asthma and COPD, there is very limited application of these models for assessment of bioequivalence of OIPs. This review also provides a ready reference of various parameters that have been considered in various models which will aid in evaluation if one model or hybrid in silico models need to be considered when assessing bioequivalence of OIPs.

目的:有许多不同的建模技术已被用于吸入药物。本综述的主要目的是对哮喘和慢性阻塞性肺疾病(COPD)吸入性药物领域已发表的数学模型进行详尽的调查。此外,本综述将尝试评估这些模型在评估口服吸入产品(oip)生物等效性(BE)方面的适用性。证据获取:检索PubMed, Science Direct, Web of Science和Scopus数据库,从1996年到2020年,找到描述哮喘/COPD吸入药物数学模型的研究。结果:50篇文章最终被纳入本系统综述。本研究确定了22篇关于硅气溶胶沉积模型的文章,20篇关于人群药代动力学的文章,8篇关于哮喘/慢性阻塞性肺病吸入药物的基于生理的药代动力学建模(PBPK)模型。在所有气溶胶沉积模式中,计算流体动力学(CFD)模拟更能预测人类呼吸道的区域气溶胶沉积模式。在整个人群PK文章中,体重、性别、年龄和吸烟状况是最常见的显著协变量。此外,有限发表的PBPK模型报告了大约29个与吸入药物吸收和分布相关的参数。每种建模技术的优点和缺点也进行了审查。结论:总体而言,虽然已有不同的建模技术用于哮喘和COPD患者的吸入药物,但这些模型在评估oip生物等效性方面的应用非常有限。本综述还提供了各种模型中考虑的各种参数的现成参考,这将有助于评估在评估oip的生物等效性时是否需要考虑单一模型或混合硅模型。
{"title":"Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.","authors":"Juliet Rebello,&nbsp;Bill Brashier,&nbsp;Sharvari Shukla","doi":"10.1007/s40199-021-00423-7","DOIUrl":"https://doi.org/10.1007/s40199-021-00423-7","url":null,"abstract":"<p><strong>Objectives: </strong>There are a multitude of different modelling techniques that have been used for inhaled drugs. The main objective of this review was to conduct an exhaustive survey of published mathematical models in the area of asthma and chronic obstructive pulmonary disease (COPD) for inhalation drugs. Additionally, this review will attempt to assess the applicability of these models to assess bioequivalence (BE) of orally inhaled products (OIPs).</p><p><strong>Evidence acquisition: </strong>PubMed, Science Direct, Web of Science, and Scopus databases were searched from 1996 to 2020, to find studies that described mathematical models used for inhaled drugs in asthma/COPD.</p><p><strong>Results: </strong>50 articles were finally included in this systematic review. This research identified 22 articles on in silico aerosol deposition models, 20 articles related to population pharmacokinetics and 8 articles on physiologically based pharmacokinetic modelling (PBPK) modelling for inhaled drugs in asthma/COPD. Among all the aerosol deposition models, computational fluid dynamics (CFD) simulations are more likely to predict regional aerosol deposition pattern in human respiratory tracts. Across the population PK articles, body weight, gender, age and smoking status were the most common covariates that were found to be significant. Further, limited published PBPK models reported approximately 29 parameters relevant for absorption and distribution of inhaled drugs. The strengths and weaknesses of each modelling technique has also been reviewed.</p><p><strong>Conclusion: </strong>Overall, while there are different modelling techniques that have been used for inhaled drugs in asthma and COPD, there is very limited application of these models for assessment of bioequivalence of OIPs. This review also provides a ready reference of various parameters that have been considered in various models which will aid in evaluation if one model or hybrid in silico models need to be considered when assessing bioequivalence of OIPs.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"30 1","pages":"229-243"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114201/pdf/40199_2021_Article_423.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10633325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Solid dispersion technology as a formulation strategy for the fabrication of modified release dosage forms: A comprehensive review. 固体分散体技术作为制备改性释放剂型的配方策略:综述。
Pub Date : 2022-06-01 DOI: 10.1007/s40199-022-00440-0
Kaushika Patel, Shreeraj Shah, Jaymin Patel

Solubility limited bioavailability is one of the crucial parameters that affect the formulation development of the new chemical entities. Thus the major constraint in the pharmaceutical product development is the suitable solubility enhancement technique for Active Pharmaceutical Ingredient. Solid dispersion (SD) is an established and preferred method for improving the solubility which ultimately may be helpful to enhance bioavailability. For long period of time Amorphous solid dispersion (ASD) have been preferred for improving solubility, but since last two decades, ASD approach have been combined with different modified release approaches to improvise the stability and site specificity of SD to grasp a hold over the specific advantages associated with such dosage forms. It is an established fact now that the SD technique not only improves solubility limited bioavailability, but it may be combined with other approaches to modify the drug release profile from the formulation as per the requirement based on the apt selection of SD carriers and suitable technology. This review covers the comprehensive overview of all such formulations where SD technology is used to serve dual purpose rather than only the sole purpose of solubility enhancement. The SD approach has been successfully implemented for some of the poorly soluble herbal drugs and still there is a vast scope of advancement in that area. The current review will provide a broad outcome in the area of SD technology for modified release formulations along with the description of current status and future prospective of SD. The SD formed by dispersing drug within the conventional carrier to form ASD increases solubility, dissolution rate and bioavailability; whereas fourth generation hydrophobic carriers provide added advantage of controlled release (CR) or sustained release (SR) profile along with enhanced stability of SD. On the other frontier, pH dependant carriers enable the SD to achieve site specificity or delayed release (DR) profile.

溶解度限制生物利用度是影响新化学实体配方发展的关键参数之一。因此,有效药物成分的溶解度增强技术是制约药品开发的主要因素。固体分散(SD)是改善溶解度的首选方法,最终可能有助于提高生物利用度。长期以来,非晶固体分散体(ASD)一直是改善溶解度的首选方法,但近二十年来,ASD方法已与不同的修饰释放方法相结合,以提高SD的稳定性和位点特异性,以掌握与此类剂型相关的特定优势。目前,SD技术不仅可以提高溶解度和有限的生物利用度,而且可以根据SD载体的选择和合适的技术,与其他方法结合,根据需要修改制剂的药物释放谱。这篇综述涵盖了所有这些配方的全面概述,其中SD技术用于双重目的,而不仅仅是提高溶解度的唯一目的。SD方法已经成功地应用于一些难溶性草药,并且在该领域仍有很大的进步空间。本综述将提供改良释药配方的SD技术领域的广泛成果,并描述SD的现状和未来前景。药物在常规载体内分散形成的SD增加了溶解度、溶出率和生物利用度;而第四代疏水载体则提供了控释(CR)或缓释(SR)的优势,并增强了SD的稳定性。在另一个前沿领域,pH依赖性载体使SD能够实现位点特异性或延迟释放(DR)特征。
{"title":"Solid dispersion technology as a formulation strategy for the fabrication of modified release dosage forms: A comprehensive review.","authors":"Kaushika Patel,&nbsp;Shreeraj Shah,&nbsp;Jaymin Patel","doi":"10.1007/s40199-022-00440-0","DOIUrl":"https://doi.org/10.1007/s40199-022-00440-0","url":null,"abstract":"<p><p>Solubility limited bioavailability is one of the crucial parameters that affect the formulation development of the new chemical entities. Thus the major constraint in the pharmaceutical product development is the suitable solubility enhancement technique for Active Pharmaceutical Ingredient. Solid dispersion (SD) is an established and preferred method for improving the solubility which ultimately may be helpful to enhance bioavailability. For long period of time Amorphous solid dispersion (ASD) have been preferred for improving solubility, but since last two decades, ASD approach have been combined with different modified release approaches to improvise the stability and site specificity of SD to grasp a hold over the specific advantages associated with such dosage forms. It is an established fact now that the SD technique not only improves solubility limited bioavailability, but it may be combined with other approaches to modify the drug release profile from the formulation as per the requirement based on the apt selection of SD carriers and suitable technology. This review covers the comprehensive overview of all such formulations where SD technology is used to serve dual purpose rather than only the sole purpose of solubility enhancement. The SD approach has been successfully implemented for some of the poorly soluble herbal drugs and still there is a vast scope of advancement in that area. The current review will provide a broad outcome in the area of SD technology for modified release formulations along with the description of current status and future prospective of SD. The SD formed by dispersing drug within the conventional carrier to form ASD increases solubility, dissolution rate and bioavailability; whereas fourth generation hydrophobic carriers provide added advantage of controlled release (CR) or sustained release (SR) profile along with enhanced stability of SD. On the other frontier, pH dependant carriers enable the SD to achieve site specificity or delayed release (DR) profile.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"30 1","pages":"165-189"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114203/pdf/40199_2022_Article_440.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9674318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents. 探索新的封盖框架:高取代基吡啶-羟肟酸衍生物作为潜在的抗增殖剂。
Pub Date : 2021-12-01 Epub Date: 2021-07-23 DOI: 10.1007/s40199-021-00406-8
Fernando Hernández-Borja, Itzel Mercado-Sánchez, Yolanda Alcaraz, Marco A García-Revilla, Clarisa Villegas Gómez, David Ordaz-Rosado, Nancy Santos-Martínez, Rocío García-Becerra, Miguel A Vazquez

Purpose: Histone deacetylases (HDACs) play a vital role in the epigenetic regulation of gene expression due to their overexpression in several cancer forms. Therefore, these enzymes are considered as a potential anticancer drug target. Different synthetic and natural structures have been studied as HDACs inhibitors; based on available structural design information, the capping group is important for the biological activity due to the different interactions in the active site entrance. The present study aimed to analyze high substituted pyridine as a capping group, which included carrying out the synthesis, antiproliferative activity analysis, and docking studies of these novel compounds.

Methods: To achieve the synthesis of these derivatives, four reaction steps were performed, generating desired products 15a-k. Their effects on cell proliferation and gene expression of p21, cyclin D1, and p53 were determined using the sulphorhodamine B (SRB) method and quantitative real-time polymerase chain reaction. The HDAC1, HDAC6, and HDAC8 isoforms were used for performing docking experiments with our 15a-k products.

Result: The products 15a-k were obtained in overall yields of 40-71%. Compounds 15j and 15k showed the highest antiproliferative activity in the breast (BT-474 and MDA-MB-231) and prostate (PC3) cancer cell lines at a concentration of 10 µM. These compounds increased p21 mRNA levels and decreased cyclin D1 and p53 gene expression. The docking study showed an increment in the strength, and in the number of interactions performed by the capping moiety of the tested molecules compared with SAHA; interactions displayed are mainly van der Waals, π-stacking, and hydrogen bond.

Conclusion: The synthesized compounds 2-thiophene (15j) and 2-furan (15k) pyridine displayed cell growth inhibition, regulation of genes related to cell cycle progression in highly metastatic cancer cell lines. The molecular coupling analysis performed with HDAC1, HDAC6 and HDAC8 showed an increment in the number of interactions performed by the capping moiety and consequently in the strength of the capping group interaction.

目的:组蛋白去乙酰化酶(Histone deacetylases, hdac)在多种癌症中过表达,在基因表达的表观遗传调控中起着重要作用。因此,这些酶被认为是潜在的抗癌药物靶点。研究了不同的合成结构和天然结构作为hdac抑制剂;根据现有的结构设计信息,由于活性位点入口的不同相互作用,盖层对生物活性很重要。本研究旨在分析作为封盖基团的高取代吡啶,包括这些新化合物的合成、抗增殖活性分析和对接研究。方法:为了合成这些衍生物,经过四个反应步骤,得到所需的产物15a-k。采用磺胺B (sulphorhodamine B, SRB)法和实时定量聚合酶链反应检测其对细胞增殖及p21、cyclin D1、p53基因表达的影响。HDAC1、HDAC6和HDAC8异构体被用于与我们的15a-k产品进行对接实验。结果:15a-k的总收率为40-71%。化合物15j和15k在浓度为10µM时对乳腺(BT-474和MDA-MB-231)和前列腺(PC3)癌细胞的抗增殖活性最高。这些化合物增加p21 mRNA水平,降低细胞周期蛋白D1和p53基因表达。对接研究表明,与SAHA相比,被测分子的capping片段在强度和相互作用次数上都有所增加;显示的相互作用主要有范德华、π堆积和氢键。结论:合成的化合物2-噻吩(15j)和2-呋喃(15k)吡啶在高转移癌细胞中具有抑制细胞生长和调控细胞周期进程相关基因的作用。与HDAC1、HDAC6和HDAC8进行的分子偶联分析显示,由capping片段进行的相互作用数量增加,从而增加了capping基团相互作用的强度。
{"title":"Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents.","authors":"Fernando Hernández-Borja,&nbsp;Itzel Mercado-Sánchez,&nbsp;Yolanda Alcaraz,&nbsp;Marco A García-Revilla,&nbsp;Clarisa Villegas Gómez,&nbsp;David Ordaz-Rosado,&nbsp;Nancy Santos-Martínez,&nbsp;Rocío García-Becerra,&nbsp;Miguel A Vazquez","doi":"10.1007/s40199-021-00406-8","DOIUrl":"https://doi.org/10.1007/s40199-021-00406-8","url":null,"abstract":"<p><strong>Purpose: </strong>Histone deacetylases (HDACs) play a vital role in the epigenetic regulation of gene expression due to their overexpression in several cancer forms. Therefore, these enzymes are considered as a potential anticancer drug target. Different synthetic and natural structures have been studied as HDACs inhibitors; based on available structural design information, the capping group is important for the biological activity due to the different interactions in the active site entrance. The present study aimed to analyze high substituted pyridine as a capping group, which included carrying out the synthesis, antiproliferative activity analysis, and docking studies of these novel compounds.</p><p><strong>Methods: </strong>To achieve the synthesis of these derivatives, four reaction steps were performed, generating desired products 15a-k. Their effects on cell proliferation and gene expression of p21, cyclin D1, and p53 were determined using the sulphorhodamine B (SRB) method and quantitative real-time polymerase chain reaction. The HDAC1, HDAC6, and HDAC8 isoforms were used for performing docking experiments with our 15a-k products.</p><p><strong>Result: </strong>The products 15a-k were obtained in overall yields of 40-71%. Compounds 15j and 15k showed the highest antiproliferative activity in the breast (BT-474 and MDA-MB-231) and prostate (PC3) cancer cell lines at a concentration of 10 µM. These compounds increased p21 mRNA levels and decreased cyclin D1 and p53 gene expression. The docking study showed an increment in the strength, and in the number of interactions performed by the capping moiety of the tested molecules compared with SAHA; interactions displayed are mainly van der Waals, π-stacking, and hydrogen bond.</p><p><strong>Conclusion: </strong>The synthesized compounds 2-thiophene (15j) and 2-furan (15k) pyridine displayed cell growth inhibition, regulation of genes related to cell cycle progression in highly metastatic cancer cell lines. The molecular coupling analysis performed with HDAC1, HDAC6 and HDAC8 showed an increment in the number of interactions performed by the capping moiety and consequently in the strength of the capping group interaction.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"291-310"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-021-00406-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39212354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An Insilico evaluation of phytocompounds from Albizia amara and Phyla nodiflora as cyclooxygenase-2 enzyme inhibitors. 金合欢和野花门植物化合物作为环氧合酶-2酶抑制剂的原位评价。
Pub Date : 2021-12-01 Epub Date: 2021-08-20 DOI: 10.1007/s40199-021-00408-6
Yukeswaran Loganathan, Manav Jain, Subhashini Thiyagarajan, Shreeranjana Shanmuganathan, Suresh Kumar Mariappan, Moni Philip Jacob Kizhakedathil, Tamilselvi Saravanakumar

Purpose: The enzyme Cyclooxygenases (COX-1 and COX-2) catalyze the formation of prostaglandin, a mediator of the inflammatory pathway. Inflammation related pathological conditions may be alleviated by targeting the Cox enzymes.COX-2 inhibitors that are currently available in the market causes undesirable side effects. Our present study focuses on the in-silico inhibition of COX -2 enzyme by the phytocompounds from Albizia amara and Phyla nodiflora.

Methods: The phytochemicals present in Albizia amara and Phyla nodiflora were analyzed for their COX-2 inhibition potential. Eight compounds from Albizia amara and eleven compounds from Phyla nodiflora obtained from GC-MS analysis was used for the current study. Molecular docking was performed using AutoDock vina. The crystal structure of COX-2 (PDB ID: 5IKR) was obtained from Protein data bank. PyMol was used to remove any solvent, organic and inorganic molecules. Energy minimization of the protein was carried out using SPDBV software. Geometrical optimizations of the ligands were performed using Avogadro software. Celecoxib was used as the positive control. ADMET properties of the compounds were analyzed using SwissADME and ProtoxII online servers. Molecular mechanics/generalized born surface area (MM/GBSA) calculations were performed to evaluate the binding efficiency. Molecular dynamics of the protein and protein-ligand complex was studied for about 100 ns using Desmond package of Schrodinger suite.

Results: Among the eighteen compounds, Squalene present in both the plants showed a better binding energy of -7.7 kcal/mol, when compare to other phytocompounds present in the extract. The control celecoxib showed a binding energy of about - 9.4 kcal/mol. The toxicity and ADMET properties of squalene indicated that it is non-toxic and followed Lipinski's rule. Molecular Dynamics (MD) analysis showed that the binding of squalene to the enzyme was stable.

Conclusion: Squalene could potentially inhibit COX2 and o wing to its properties, squalene can be formulated in gels/creams and could be possibly used for external edema and inflammation.

目的:环氧化酶(COX-1和COX-2)催化前列腺素的形成,前列腺素是炎症途径的介质。炎症相关的病理状况可能通过靶向Cox酶而得到缓解。目前市场上可用的COX-2抑制剂会产生不良副作用。本文主要研究了合欢和野花门植物化合物对COX -2酶的体外抑制作用。方法:分析合欢和野花门植物化学成分对COX-2的抑制作用。本研究采用气相色谱-质谱分析得到的8个产自合欢的化合物和11个产自野花门的化合物。分子对接使用AutoDock vina进行。从蛋白质数据库中获得COX-2的晶体结构(PDB ID: 5IKR)。PyMol用于去除任何溶剂,有机和无机分子。利用SPDBV软件对蛋白质进行能量最小化。利用阿伏伽德罗软件对配体进行几何优化。以塞来昔布为阳性对照。使用SwissADME和ProtoxII在线服务器分析化合物的ADMET性质。通过分子力学/广义出生表面积(MM/GBSA)计算来评估结合效率。利用薛定谔套件的Desmond包对蛋白及其配体复合物进行了约100 ns的分子动力学研究。结果:在这18种化合物中,角鲨烯的结合能为-7.7 kcal/mol。对照塞来昔布的结合能约为- 9.4 kcal/mol。角鲨烯的毒性和ADMET性质表明它是无毒的,符合利平斯基规则。分子动力学(MD)分析表明,角鲨烯与酶的结合是稳定的。结论:角鲨烯具有抑制COX2的作用,可用于凝胶/面霜的制备,可用于体外水肿和炎症的治疗。
{"title":"An Insilico evaluation of phytocompounds from Albizia amara and Phyla nodiflora as cyclooxygenase-2 enzyme inhibitors.","authors":"Yukeswaran Loganathan,&nbsp;Manav Jain,&nbsp;Subhashini Thiyagarajan,&nbsp;Shreeranjana Shanmuganathan,&nbsp;Suresh Kumar Mariappan,&nbsp;Moni Philip Jacob Kizhakedathil,&nbsp;Tamilselvi Saravanakumar","doi":"10.1007/s40199-021-00408-6","DOIUrl":"https://doi.org/10.1007/s40199-021-00408-6","url":null,"abstract":"<p><strong>Purpose: </strong>The enzyme Cyclooxygenases (COX-1 and COX-2) catalyze the formation of prostaglandin, a mediator of the inflammatory pathway. Inflammation related pathological conditions may be alleviated by targeting the Cox enzymes.COX-2 inhibitors that are currently available in the market causes undesirable side effects. Our present study focuses on the in-silico inhibition of COX -2 enzyme by the phytocompounds from Albizia amara and Phyla nodiflora.</p><p><strong>Methods: </strong>The phytochemicals present in Albizia amara and Phyla nodiflora were analyzed for their COX-2 inhibition potential. Eight compounds from Albizia amara and eleven compounds from Phyla nodiflora obtained from GC-MS analysis was used for the current study. Molecular docking was performed using AutoDock vina. The crystal structure of COX-2 (PDB ID: 5IKR) was obtained from Protein data bank. PyMol was used to remove any solvent, organic and inorganic molecules. Energy minimization of the protein was carried out using SPDBV software. Geometrical optimizations of the ligands were performed using Avogadro software. Celecoxib was used as the positive control. ADMET properties of the compounds were analyzed using SwissADME and ProtoxII online servers. Molecular mechanics/generalized born surface area (MM/GBSA) calculations were performed to evaluate the binding efficiency. Molecular dynamics of the protein and protein-ligand complex was studied for about 100 ns using Desmond package of Schrodinger suite.</p><p><strong>Results: </strong>Among the eighteen compounds, Squalene present in both the plants showed a better binding energy of -7.7 kcal/mol, when compare to other phytocompounds present in the extract. The control celecoxib showed a binding energy of about - 9.4 kcal/mol. The toxicity and ADMET properties of squalene indicated that it is non-toxic and followed Lipinski's rule. Molecular Dynamics (MD) analysis showed that the binding of squalene to the enzyme was stable.</p><p><strong>Conclusion: </strong>Squalene could potentially inhibit COX2 and o wing to its properties, squalene can be formulated in gels/creams and could be possibly used for external edema and inflammation.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"311-320"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602612/pdf/40199_2021_Article_408.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39329528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial. 二甲双胍治疗纤维囊性乳腺疾病:一项安慰剂对照随机临床试验
Pub Date : 2021-12-01 Epub Date: 2021-10-31 DOI: 10.1007/s40199-021-00424-6
Sadaf Alipour, Hadith Rastad, Azin Saberi, Firoozeh Faiz, Arezoo Maleki-Hajiagha, Mahboubeh Abedi

Background and purpose: Fibrocystic disease (FCD) of the breast as a very common health problem in women has estrogen-dependent and proliferative features. No effective management strategy has been validated for this disorder, so far. The anti-hyperglycemic agent metformin has both anti-proliferative and estrogen-suppressing effects. Thus, we investigated metformin as a management strategy for FCD.

Methods: The study was a double-blind placebo-controlled randomized clinical trial. Premenopausal women with FCD according to history, physical exam and ultrasound, who had measurable microcyst clusters on ultrasound (US) were entered the study. Oral placebo and metformin tablets (500 mg) were used twice daily by participants in the intervention and control groups. Size and number of microcyst clusters on US and the subjective pain score were recorded before and after the intervention.

Results: 154 participants were randomly allocated into two groups of 77 interventions and 77 controls. The decrease in size of the largest microcyst cluster in each patient and the mean decrease in number of microcyst clusters were not statistically significant (P = 0.310 and P = 0.637, respectively). However, those microcyst clusters which were ≥ 14 mm became significantly smaller after metformin use (P = 0.006). Additionally, in the subset of participants with pain at baseline, a larger proportion in the intervention group experienced at least 50% reduction in pain score (63.8% (30/47) in the intervention vs. 44.2% (19/43) in the placebo groups, P = 0.031).

Conclusion: Our study showed that metformin might be effective in the management of FCD. Further studies are proposed for confirmation of this subject.

背景和目的:乳腺纤维囊性疾病(FCD)是女性非常常见的健康问题,具有雌激素依赖性和增生性特征。到目前为止,还没有有效的治疗这种疾病的策略。降糖药二甲双胍具有抗增殖和抑制雌激素的作用。因此,我们研究了二甲双胍作为FCD的管理策略。方法:采用双盲、安慰剂对照的随机临床试验。研究对象为经病史、体格检查和超声检查均可检测到微囊团簇的绝经前FCD妇女。干预组和对照组的参与者每天使用两次口服安慰剂和二甲双胍片(500毫克)。在干预前后分别记录US上微囊簇的大小和数量以及主观疼痛评分。结果:154名参与者被随机分为两组,77名干预组和77名对照组。每位患者最大微囊团簇大小的减少和平均微囊团簇数量的减少均无统计学意义(P = 0.310和P = 0.637)。而≥14 mm的微囊团簇在使用二甲双胍后明显变小(P = 0.006)。此外,在基线疼痛的参与者子集中,干预组中更大比例的参与者疼痛评分至少降低了50%(干预组为63.8%(30/47),安慰剂组为44.2% (19/43),P = 0.031)。结论:本研究表明二甲双胍治疗FCD可能有效。建议进一步研究以证实这一问题。
{"title":"Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial.","authors":"Sadaf Alipour,&nbsp;Hadith Rastad,&nbsp;Azin Saberi,&nbsp;Firoozeh Faiz,&nbsp;Arezoo Maleki-Hajiagha,&nbsp;Mahboubeh Abedi","doi":"10.1007/s40199-021-00424-6","DOIUrl":"https://doi.org/10.1007/s40199-021-00424-6","url":null,"abstract":"<p><strong>Background and purpose: </strong>Fibrocystic disease (FCD) of the breast as a very common health problem in women has estrogen-dependent and proliferative features. No effective management strategy has been validated for this disorder, so far. The anti-hyperglycemic agent metformin has both anti-proliferative and estrogen-suppressing effects. Thus, we investigated metformin as a management strategy for FCD.</p><p><strong>Methods: </strong>The study was a double-blind placebo-controlled randomized clinical trial. Premenopausal women with FCD according to history, physical exam and ultrasound, who had measurable microcyst clusters on ultrasound (US) were entered the study. Oral placebo and metformin tablets (500 mg) were used twice daily by participants in the intervention and control groups. Size and number of microcyst clusters on US and the subjective pain score were recorded before and after the intervention.</p><p><strong>Results: </strong>154 participants were randomly allocated into two groups of 77 interventions and 77 controls. The decrease in size of the largest microcyst cluster in each patient and the mean decrease in number of microcyst clusters were not statistically significant (P = 0.310 and P = 0.637, respectively). However, those microcyst clusters which were ≥ 14 mm became significantly smaller after metformin use (P = 0.006). Additionally, in the subset of participants with pain at baseline, a larger proportion in the intervention group experienced at least 50% reduction in pain score (63.8% (30/47) in the intervention vs. 44.2% (19/43) in the placebo groups, P = 0.031).</p><p><strong>Conclusion: </strong>Our study showed that metformin might be effective in the management of FCD. Further studies are proposed for confirmation of this subject.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"389-396"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39577529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Enhancement of the transdermal delivery of zidovudine by pretreating the skin with two physical enhancers: microneedles and sonophoresis. 通过用两种物理增强剂预处理皮肤:微针和超声导入来增强齐多夫定的透皮递送。
Pub Date : 2021-12-01 Epub Date: 2021-07-03 DOI: 10.1007/s40199-021-00402-y
Irene de Jesús Martínez-Segoviano, Adriana Ganem-Rondero

Background: Zidovudine (AZT) has been the most widely used drug for antiretroviral therapy. In order to improve the therapy with this drug, different alternatives have been proposed, such as the transdermal administration. The use of permeation enhancers is necessary to favor the passage of this drug through the skin, due to its physicochemical properties and to the natural permeation barrier imposed by the skin.

Objectives: To evaluate the effect of two permeation enhancers, sonophoresis and microneedles, on the permeability of AZT through the skin.

Methods: Permeation studies with an AZT solution were performed using pigskin clamped in Franz-type cells. Sonophoresis was applied under different conditions (i.e., amplitude, duty cycle and application time), selected according to an experimental design, where the response variables were the increase in temperature of the skin surface and the increase in transepidermal water loss. ATR-FTIR was also used to demonstrate the effect of enhancers on membrane components.

Results: The permeability of AZT through intact skin was very poor, with a very long lag time. Pretreatment of the skin with sonophoresis increased AZT transport significantly, reducing the lag time. The maximum flux (27.52 µgcm-2 h-1) and the highest total amount permeated (about 624 µg/cm2) were obtained when applying sonophoresis in continuous mode, with an amplitude of 20%, and an application time of 2 min. Sonophoresis appears to have an impact on stratum corneum proteins. The use of microneedles further increased the flux (30.41 µgcm-2 h-1) and the total amount permeated (about 916 µg/cm2), relative to sonophoresis.

Conclusion: The results are encouraging in terms of promoting AZT transport through the skin using sonophoresis or microneedles as permeation enhancers.

背景:齐多夫定(AZT)是抗逆转录病毒治疗中应用最广泛的药物。为了改善这种药物的治疗,已经提出了不同的替代方案,如经皮给药。由于其物理化学性质和皮肤施加的天然渗透屏障,使用渗透增强剂对于促进药物通过皮肤是必要的。目的:评价超声和微针两种渗透增强剂对AZT经皮渗透的影响。方法:采用猪皮夹持法观察AZT溶液对弗兰兹型细胞的渗透作用。根据实验设计选择不同的条件(即振幅、占空比和应用时间),其中响应变量为皮肤表面温度的升高和经皮失水的增加。ATR-FTIR也用于证明增强剂对膜组分的影响。结果:AZT在完整皮肤中的渗透性很差,滞后期很长。皮肤超声预处理显著增加AZT转运,减少延迟时间。超声电泳在连续模式下,振幅为20%,时间为2min,获得最大通量(27.52µgcm-2 h-1)和最高总渗透量(约624µg/cm2)。超声电泳似乎对角质层蛋白有影响。相对于声泳,微针的使用进一步增加了通量(30.41µgcm-2 h-1)和总渗透量(约916µg/cm2)。结论:超声透入或微针透入促进AZT通过皮肤转运的结果令人鼓舞。
{"title":"Enhancement of the transdermal delivery of zidovudine by pretreating the skin with two physical enhancers: microneedles and sonophoresis.","authors":"Irene de Jesús Martínez-Segoviano,&nbsp;Adriana Ganem-Rondero","doi":"10.1007/s40199-021-00402-y","DOIUrl":"https://doi.org/10.1007/s40199-021-00402-y","url":null,"abstract":"<p><strong>Background: </strong>Zidovudine (AZT) has been the most widely used drug for antiretroviral therapy. In order to improve the therapy with this drug, different alternatives have been proposed, such as the transdermal administration. The use of permeation enhancers is necessary to favor the passage of this drug through the skin, due to its physicochemical properties and to the natural permeation barrier imposed by the skin.</p><p><strong>Objectives: </strong>To evaluate the effect of two permeation enhancers, sonophoresis and microneedles, on the permeability of AZT through the skin.</p><p><strong>Methods: </strong>Permeation studies with an AZT solution were performed using pigskin clamped in Franz-type cells. Sonophoresis was applied under different conditions (i.e., amplitude, duty cycle and application time), selected according to an experimental design, where the response variables were the increase in temperature of the skin surface and the increase in transepidermal water loss. ATR-FTIR was also used to demonstrate the effect of enhancers on membrane components.</p><p><strong>Results: </strong>The permeability of AZT through intact skin was very poor, with a very long lag time. Pretreatment of the skin with sonophoresis increased AZT transport significantly, reducing the lag time. The maximum flux (27.52 µgcm<sup>-2</sup> h<sup>-1</sup>) and the highest total amount permeated (about 624 µg/cm<sup>2</sup>) were obtained when applying sonophoresis in continuous mode, with an amplitude of 20%, and an application time of 2 min. Sonophoresis appears to have an impact on stratum corneum proteins. The use of microneedles further increased the flux (30.41 µgcm<sup>-2</sup> h<sup>-1</sup>) and the total amount permeated (about 916 µg/cm<sup>2</sup>), relative to sonophoresis.</p><p><strong>Conclusion: </strong>The results are encouraging in terms of promoting AZT transport through the skin using sonophoresis or microneedles as permeation enhancers.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"279-290"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40199-021-00402-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39144817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1